TrialJournal of cancer research and clinical oncology2021

Overall survival of super-elderly (85 years or older) advanced non-small cell lung cancer patients with active epidermal growth factor receptor mutations receiving first-line gefitinib therapy: a single-institute retrospective study.

Kosuke Kashiwabara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.